Gyre Therapeutics Financial Ratios
NASDAQ: GYREHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Gyre Therapeutics ratio analysis
Gyre Therapeutics earned a net margin of 8.5% in FY 2025, down from 16.9% a year earlier. Gross margin was 95.4% compared with a median of 95.9% over the prior 3 years. Return on equity reached 15.8%, meaning Gyre Therapeutics generated 0.16 dollars of profit for every dollar of shareholders' equity.
At the end of FY 2025, GYRE traded at 340.5 times earnings; across the 3 fiscal years shown, its year-end P/E ranged from 215.8 to 340.5, with a median of 265.0. Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
Gyre Therapeutics financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| P/E ratio (at fiscal year end) | 340.50 | 215.80 | — | 265.00 | — | — | — | — | — | — |
| Price / sales | 5.22 | 8.68 | 14.91 | 4.94 | 57.00 | 86.66 | — | 263,245.93 | 688.14 | — |
| Price / book | 9.74 | 14.50 | — | 11.89 | 10.18 | 23.86 | 17.21 | 13.17 | 22.76 | 7.09 |
| Gross margin | 95.4% | 96.3% | 95.9% | 95.3% | — | — | — | — | — | — |
| Operating margin | 9.9% | 15.3% | -59.3% | 9.0% | -1,197.8% | -273.9% | — | -563,700.0% | -2,143.6% | — |
| Net margin | 8.5% | 16.9% | -75.3% | 4.2% | -1,198.3% | -268.5% | — | -500,916.7% | -2,118.0% | — |
| Free cash flow margin | -0.2% | -5.6% | 15.3% | 5.6% | -1,152.8% | -262.8% | — | -482,150.0% | -1,961.0% | — |
| Return on equity (ROE) | 15.8% | 28.3% | — | 10.1% | -214.0% | -73.9% | -80.7% | -25.1% | -70.1% | -105.4% |
| Return on assets (ROA) | 4.5% | 14.3% | -73.3% | 5.1% | -158.0% | -59.3% | -56.0% | -24.1% | -54.6% | -44.5% |
| Current ratio | 6.28 | 3.32 | 2.85 | 4.06 | 3.63 | 5.03 | 3.32 | 25.83 | 4.48 | 1.71 |
| Revenue growth | 10.2% | -6.8% | 10.9% | 1,294.0% | -65.0% | — | — | -99.4% | — | — |
| EPS growth | -60.0% | — | -4,800.0% | — | — | — | — | — | — | — |